Evidence map›Paper›PMID 36808558›Full record

ReviewCurrent oncology reports2023

Approaches to Oligometastatic Renal Cell Carcinoma.

Nicolas Magne, Nicolas Milhade, Paul Sargos, Wafa Bouleftour

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Nicolas MagneDepartment of Radiation Oncology, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France. n.magne@bordeaux.unicancer.fr.
Nicolas MilhadeDepartment of Radiation Oncology, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France.
Paul SargosDepartment of Radiation Oncology, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France.
Wafa BouleftourDepartment of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France.ORCID 0000-0002-8485-9386
Institut Bergonié · FRCentre Hospitalier Universitaire de Saint-Étienne · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis study aims to gather the current state of the literature about therapeutic approaches and management of oligometastatic renal cell carcinoma. RECENT

findingsTwo recent stereotactic body radiotherapy (SBRT) studies gained attention and offered a promising outcome alone or in association with antineoplastic drugs especially in oligometastatic renal cell carcinoma. If one can consider evidence-based medicine as the sole therapeutic option, many unresolved questions are still pending. Thus, therapeutic approaches in oligometastatic renal cell carcinoma are still working. Further phase III clinical trials are urgently needed to validate the last 2 phase II involving SBRT and improve knowledge for defining the right care to the right patient at the right time. In addition, a discussion in a disciplinary consultation meeting remains essential to validate the arrangement between systemic treatments and focal treatments that will best benefit the patient.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsRadiosurgeryHumansBiomarkerImmunotherapyOligometastasesRadiofrequencyRenal cell carcinomaStereotactic body radiation therapyTargeted therapy

Identifiers

PMID36808558
OpenAlexW4321352789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.